SCL Science

SCL Science FCF Growth

The Year-over-Year Free Cash Flow Growth of SCL Science (246960.KQ) as of Nov 18, 2026 is 45.47 %. In the previous year, Year-over-Year Free Cash Flow Growth was -48.83 % — a change of -193.12% (higher).

FCF Growth

45.47 %

YoY

-193.12%

Last updated:

Year-over-Year Free Cash Flow Growth of SCL Science is 2025 45.47 % . Year-over-Year Free Cash Flow Growth of SCL Science was 2024 -48.83 % . It decreases by -193.12% higher compared to the previous year.

The SCL Science FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
4.95 KRW
Jan 1, 2019
-60.81 KRW
Jan 1, 2020
-32.14 KRW
Jan 1, 2021
-120.17 KRW
Jan 1, 2022
51.63 KRW
Jan 1, 2023
-14.48 KRW
Jan 1, 2024
-48.83 KRW
Jan 1, 2025
45.47 KRW
The SCL Science FCF Growth history
YEARFCF GrowthYoY
45.47 %-193.12%
-48.83 %+237.20%
-14.48 %-128.05%
51.63 %-142.96%
-120.17 %+273.84%
-32.14 %-47.14%
-60.81 %-1,328.01%
4.95 %-190.85%
-5.45 %-114.35%
37.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Year-over-Year Free Cash Flow Growth of SCL Science is 45.47 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth SCL Science since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's SCL Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — SCL Science

All Key Metrics — SCL Science